Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Real-world data on the long-term effectiveness of the anti-IL17 agent Secukinumab in treating moderate-to-severe HS showed a 56.5% maximal response rate (evaluated in terms of HiSCR and IHS4 reduction of at least 50%) at 6 months and dropout exceeding 40% at 1 year of treatment [235]
The short half-life of the No-DAC variant ensures GH pulses remain physiological and transient, reducing the risk of desensitization observed with long-term continuous GH exposure
Researchers in the Product Research Team at ProSource were at the forefront of this area of investigation
a diagnostic accuracy study
Ask your friends and family to tell their stories and submit these as comments
)
